Viridian Therapeutics
VRDN
46 hedge funds and large institutions have $25M invested in Viridian Therapeutics in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.23% less ownership
Funds ownership: 2.86% → 2.63% (-0.23%)
10% less funds holding
Funds holding: 51 → 46 (-5)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
33% less capital invested
Capital invested by funds: $37.4M → $25M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.4M |
| 2 |
Goldman Sachs
New York
|
+$1.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$453K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$312K |
| 5 |
Jane Street
New York
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.66M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$993K |
| 4 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
-$430K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$229K |
VRDN Hedge Fund Activity: Q2 2019 in Review
46 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2019, worth a combined $25M — down 33% from $37.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VRDN and 10 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $1.4M. The largest seller was BlackRock, cutting an estimated $2.66M.
- 46 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2019, down from 51 in Q1 2019.
- Funds reported $25M of Viridian Therapeutics stock for Q2 2019, down 33% quarter-over-quarter.
- 10 funds opened new Viridian Therapeutics positions in Q2 2019 and 12 closed out, a net change of -2 holders.
- The largest Viridian Therapeutics buyer in Q2 2019 was Millennium Management, an estimated $1.4M added.
- The largest Viridian Therapeutics seller in Q2 2019 was BlackRock, an estimated $2.66M sold.
Based on aggregated 13F filings for Q2 2019.